Trumab 150 Injection is a medication used to treat HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Cancer is characterized by the abnormal growth and uncontrolled division of cells. This medication can also be utilized when cancer has metastasized to other areas of the body.
The active ingredient in Trumab 150 Injection is Trastuzumab, which is classified as a monoclonal antibody. It functions by inhibiting the abnormal proliferation of cancer cells, ultimately leading to the activation of programmed cell death.
Patients may experience side effects from Trumab 150 Injection, including abdominal pain, chills, diarrhea, fatigue, nausea, back pain, bone pain, edema, insomnia, fever, dizziness, headache, vomiting, cough, rash, and reactions at the injection site. If these side effects persist or become bothersome, it is important to consult your doctor. Trumab 150 Injection should only be administered by a qualified healthcare professional; self-administration is not advised.
If you have an allergy to Trumab 150 Injection or any of its components, you should avoid using it and inform your doctor. Additionally, notify your doctor if you have any cardiovascular issues, lung conditions, or liver or kidney diseases, as these may lead to adverse reactions. Trumab 150 Injection is associated with embryo-fetal toxicity, so if you are pregnant or breastfeeding, it is crucial to inform your doctor in advance.
